Literature DB >> 21458536

The time course of acquired epilepsy: implications for therapeutic intervention to suppress epileptogenesis.

F Edward Dudek1, Kevin J Staley.   

Abstract

Relatively little is known about the time course of the development of spontaneous recurrent seizures (i.e., epileptogenesis) after brain injury in human patients, or even in animal models. This time course is determined, at least in part, by the underlying molecular and cellular mechanisms responsible for acquired epilepsy. An understanding of the critical mechanistic features of acquired epilepsy will be useful, if not essential, for developing strategies to block or suppress epileptogenesis. Here, data on the time course of the development of spontaneous recurrent seizures are summarized from experiments using nearly continuous electrographic (EEG) recordings in (1) kainate-treated rats, which are a model of temporal lobe epilepsy, and (2) rats subjected to unilateral carotid occlusion with superimposed hypoxia at postnatal day 7, which is a model of perinatal stroke. Although the classical view of the development of epileptogenesis is a step-function of time after the brain injury, with a latent period present between the brain injury and the first unprovoked seizure, the data described here show that seizure frequency was a sigmoid function of time after the insult in both animal models. Furthermore, the spontaneous recurrent seizures often occurred in clusters, even shortly after the first spontaneous seizure. These data suggest that (1) epileptogenesis is a continuous process that extends past the first spontaneous clinical seizure, (2) seizure clusters can obscure this continuous process, and (3) the potential time for administration of a therapy to suppress acquired epilepsy extends well past the first clinical seizure.
Copyright © 2011. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21458536     DOI: 10.1016/j.neulet.2011.03.071

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  25 in total

Review 1.  Prospects for imaging-related biomarkers of human epileptogenesis: a critical review.

Authors:  William A Gomes; Shlomo Shinnar
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

Review 2.  Defining "epileptogenesis" and identifying "antiepileptogenic targets" in animal models of acquired temporal lobe epilepsy is not as simple as it might seem.

Authors:  Robert S Sloviter; Argyle V Bumanglag
Journal:  Neuropharmacology       Date:  2012-02-04       Impact factor: 5.250

3.  Altered Expression Pattern of Acid-Sensing Ion Channel Isoforms in Piriform Cortex After Seizures.

Authors:  Hao Wu; Chao Wang; Bei Liu; Huanfa Li; Yu Zhang; Shan Dong; Guodong Gao; Hua Zhang
Journal:  Mol Neurobiol       Date:  2015-03-07       Impact factor: 5.590

Review 4.  Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design.

Authors:  Michele Simonato; Wolfgang Löscher; Andrew J Cole; F Edward Dudek; Jerome Engel; Rafal M Kaminski; Jeffrey A Loeb; Helen Scharfman; Kevin J Staley; Libor Velíšek; Henrik Klitgaard
Journal:  Epilepsia       Date:  2012-06-18       Impact factor: 5.864

5.  New strategies for preventing epileptogenesis: perspective and overview.

Authors:  Hal Blumenfeld
Journal:  Neurosci Lett       Date:  2011-02-24       Impact factor: 3.046

Review 6.  Epileptogenesis.

Authors:  Asla Pitkänen; Katarzyna Lukasiuk; F Edward Dudek; Kevin J Staley
Journal:  Cold Spring Harb Perspect Med       Date:  2015-09-18       Impact factor: 6.915

7.  Imaging increased glutamate in children with Sturge-Weber syndrome: Association with epilepsy severity.

Authors:  Csaba Juhász; Jiani Hu; Yang Xuan; Harry T Chugani
Journal:  Epilepsy Res       Date:  2016-02-27       Impact factor: 3.045

8.  Early susceptibility for epileptiform activity in malformed cortex.

Authors:  Andrew Bell; Kimberle M Jacobs
Journal:  Epilepsy Res       Date:  2013-12-01       Impact factor: 3.045

9.  Diphenytoin, riluzole and lidocaine: three sodium channel blockers, with different mechanisms of action, decrease hippocampal epileptiform activity.

Authors:  Lihong Diao; Jennifer L Hellier; Jessica Uskert-Newsom; Philip A Williams; Kevin J Staley; Audrey S Yee
Journal:  Neuropharmacology       Date:  2013-05-21       Impact factor: 5.250

10.  Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis.

Authors:  Rebecca L Williams-Karnesky; Ursula S Sandau; Theresa A Lusardi; Nikki K Lytle; Joseph M Farrell; Eleanor M Pritchard; David L Kaplan; Detlev Boison
Journal:  J Clin Invest       Date:  2013-07-25       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.